Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 16/20 | 0.49 |
| ▸ | BRAF | P15056 | 3/20 | 0.41 |
| ▸ | STK25 | O00506 | 1/20 | 0.41 |
| ▸ | CIT | O14578 | 1/20 | 0.41 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.41 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.41 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.41 |
| ▸ | PAK3 | O75914 | 1/20 | 0.41 |
| ▸ | STK10 | O94804 | 1/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.41 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | LCK | P06239 | 1/20 | 0.41 |
| ▸ | FYN | P06241 | 1/20 | 0.41 |
| ▸ | CSF1R | P07333 | 1/20 | 0.41 |
| ▸ | YES1 | P07947 | 1/20 | 0.41 |
| ▸ | LYN | P07948 | 1/20 | 0.41 |
| ▸ | RET | P07949 | 1/20 | 0.41 |
| ▸ | MET | P08581 | 1/20 | 0.41 |
| ▸ | HCK | P08631 | 1/20 | 0.41 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3675472 | 0.76 | RAF1 (0.39) | RAF1 | |
| SCHEMBL30151211 | 0.76 | NPY5R (0.54) | — | |
| SCHEMBL11252204 | 0.75 | DGAT1 (0.47) | RAF1 | |
| SCHEMBL25754916 | 0.73 | SCN2A (0.51) | — | |
| SCHEMBL11260682 | 0.73 | DGAT1 (0.40) | — | |
| SCHEMBL12852957 | 0.73 | RAF1 (0.64) | RAF1BRAFSTK25CITEPHB6 | |
| SCHEMBL15347521 | 0.72 | AURKA (0.39) | RAF1KDR | |
| SCHEMBL30077144 | 0.72 | AURKA (0.39) | RAF1KDR | |
| SCHEMBL5442233 | 0.71 | IDO1 (0.36) | MAP4K4 | |
| SCHEMBL13167342 | 0.70 | RAF1 (0.69) | RAF1BRAFSTK25CITEPHB6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8592459-B2 | Substituted benzimidazoles and methods of their use | NOVARTIS AG (CH) | 2013-11-26 | — | — | US | disclosed |
| CN-101253168-B | Substituted benzimidazoles as kinase inhibitors | NOVARTIS AG | 2012-12-12 | — | — | CN | disclosed |
| CN-101253169-B | Substituted benzimidazoles and processes for their preparation | NOVARTIS AG | 2011-11-23 | — | — | CN | disclosed |
| EP-1926722-B1 | SUBSTITUTED BENZIMIDAZOLES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2011-09-28 | — | — | EP | disclosed |
| EP-1926722-B1 | SUBSTITUTED BENZIMIDAZOLES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2011-09-28 | — | — | EP | disclosed |
| EP-1924577-B1 | SUBSTITUTED BENZIMIDAZOLES AND METHODS OF PREPARATION | NOVARTIS AG (CH) | 2011-03-30 | — | — | EP | disclosed |
| EP-1924577-B1 | SUBSTITUTED BENZIMIDAZOLES AND METHODS OF PREPARATION | NOVARTIS AG (CH) | 2011-03-30 | — | — | EP | disclosed |
| US-20100256375-A1 | SUBSTITUTED BENZIMIDAZOLES AND METHODS OF PREPARATION | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2010-10-07 | — | — | US | disclosed |
| US-20100256375-A1 | SUBSTITUTED BENZIMIDAZOLES AND METHODS OF PREPARATION | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2010-10-07 | — | — | US | disclosed |
| US-20100234394-A1 | SUBSTITUTED BENZIMIDAZOLES AND METHODS OF THEIR USE | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2010-09-16 | — | — | US | disclosed |
| US-20070161680-A1 | Substituted benzimidazoles and methods of their use | NOVARTIS AG | 2007-07-12 | — | — | US | disclosed |
| US-20070161680-A1 | Substituted benzimidazoles and methods of their use | NOVARTIS AG | 2007-07-12 | — | — | US | disclosed |
| US-20070161680-A1 | Substituted benzimidazoles and methods of their use | NOVARTIS AG | 2007-07-12 | — | — | US | disclosed |
| WO-2007030377-A1 | SUBSTITUTED BENZIMIDAZOLES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2007-03-15 | — | — | WO | disclosed |
| WO-2007030377-A1 | SUBSTITUTED BENZIMIDAZOLES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2007-03-15 | — | — | WO | disclosed |
| WO-2007027950-A1 | SUBSTITUTED BENZIMIDAZOLES AND METHODS OF PREPARATION | NOVARTIS AG (CH) | 2007-03-08 | — | — | WO | disclosed |
| WO-2007027950-A1 | SUBSTITUTED BENZIMIDAZOLES AND METHODS OF PREPARATION | NOVARTIS AG (CH) | 2007-03-08 | — | — | WO | disclosed |
| US-20070049622-A1 | Substituted benzimidazoles and methods of preparation | NOVARTIS AG | 2007-03-01 | — | — | US | disclosed |
| US-20070049622-A1 | Substituted benzimidazoles and methods of preparation | NOVARTIS AG | 2007-03-01 | — | — | US | disclosed |
| US-20070049622-A1 | Substituted benzimidazoles and methods of preparation | NOVARTIS AG | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049622-A1 | Substituted benzimidazoles and methods of preparation | ABL1, CDK2, KIT | RAF1 73/4885BRAF 29/4885STK25 597/4885 |
| US-20070161680-A1 | Substituted benzimidazoles and methods of their use | BRAF, DSTYK, CHEK2 | RAF1 57/4885BRAF 1/4885STK25 82/4885 |
| US-20100256375-A1 | SUBSTITUTED BENZIMIDAZOLES AND METHODS OF PREPARATION | ABL1, CDK2, KIT | RAF1 73/4885BRAF 29/4885STK25 597/4885 |
| US-20100234394-A1 | SUBSTITUTED BENZIMIDAZOLES AND METHODS OF THEIR USE | BRAF, DSTYK, CHEK2 | RAF1 57/4885BRAF 1/4885STK25 82/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.